Biomarin Pharmaceutical vs United Therapeutics
Biomarin Pharmaceutical and United Therapeutics are similar in size: $3.22bn and $3.18bn of revenue in their latest fiscal years. Biomarin Pharmaceutical grew faster (12.9% against 10.6%). United Therapeutics kept more of each dollar of sales as profit: a net margin of 41.9% against 10.8%.
| Latest fiscal year | Biomarin PharmaceuticalBMRN, 2025 | United TherapeuticsUTHR, 2025 |
|---|---|---|
| Revenue | $3.22bn | $3.18bn |
| Revenue growth | 12.9% | 10.6% |
| Net income | $349m | $1.33bn |
| Operating margin | 12.7% | 46.9% |
| Net margin | 10.8% | 41.9% |
| Return on equity | 5.9% | 19.7% |
| Free cash flow | $725m | $1.04bn |
| Cash | $1.31bn | $1.56bn |
| Total debt | $600m | — |
| Debt to equity | 9.9% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $1.00bn |
| Employees | 3,221 | 1,400 |
| Market value | $10.80bn | $25.65bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 40 (Weak) | 75 (Strong) |
| Insider trades, 12 months | 0 buys, 5 sales | 1 buys, 2808 sales |